Clinical Trials Logo

Plasmacytoma clinical trials

View clinical trials related to Plasmacytoma.

Filter by:

NCT ID: NCT00025415 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Start date: August 2001
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction

NCT ID: NCT00022607 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: January 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. It is not yet known whether bevacizumab works better with or without thalidomide for multiple myeloma. PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without thalidomide in treating patients who have relapsed or refractory multiple myeloma.

NCT ID: NCT00022282 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: April 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: AE-941 may help to slow the growth of multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who have relapsed or refractory multiple myeloma.

NCT ID: NCT00021359 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Start date: August 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with dexamethasone may be an effective treatment for multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of combining isotretinoin and dexamethasone in treating patients who have multiple myeloma.

NCT ID: NCT00019097 Completed - Clinical trials for Stage III Multiple Myeloma

Vaccine Therapy in Treating Patients With Multiple Myeloma

Start date: July 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus vaccine therapy and chemotherapy in treating patients who have multiple myeloma.

NCT ID: NCT00017602 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: December 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the drug. It is not yet known if dexamethasone is more effective with or without oblimersen in treating multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with or without oblimersen in treating patients who have relapsed or refractory multiple myeloma.

NCT ID: NCT00015925 Completed - Leukemia Clinical Trials

MS-275 in Treating Patients With Hematologic Cancer

Start date: February 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.

NCT ID: NCT00014508 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Start date: November 19, 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous peripheral stem cell transplantation and donor peripheral stem cell transplantation in treating patients who have multiple myeloma.

NCT ID: NCT00014482 Completed - Depression Clinical Trials

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

Start date: December 2000
Phase: N/A
Study type: Interventional

RATIONALE: Music therapy may be effective in relieving pain and emotional distress in patients who are undergoing cancer therapy. PURPOSE: Randomized trial to determine the effectiveness of music therapy to ease pain and emotional distress in patients with hematologic cancer who are undergoing high-dose therapy and stem cell transplantation.

NCT ID: NCT00010283 Completed - Breast Cancer Clinical Trials

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.